Ptc Therapeutics shares owned by Simplex Trading
Quarter-by-quarter ownership of Ptc Therapeutics shares owned by Simplex Trading
from 13F filings
Historical chart of Simplex Trading investment in Ptc Therapeutics
Tip: Access up to 7 years of quarterly data
All positions including Ptc Therapeutics held by Simplex Trading consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Ptc Therapeutics by Simplex Trading
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2025-09-30 | $276k | 4.5k | 61.33 |
| 2025-06-30 | $190k | 3.9k | 48.72 |
| 2025-03-31 | $101k | 2.0k | 50.50 |
| 2024-12-31 | $72k | 1.6k | 45.00 |
| 2024-06-30 | $715k | 23k | 30.56 |
| 2024-03-31 | $40k | 1.4k | 28.57 |
| 2023-12-31 | $3.2M | 117k | 27.56 |
| 2023-09-30 | $710k | 32k | 22.40 |
| 2023-06-30 | $654k | 16k | 40.62 |
| 2023-03-31 | $1.1M | 23k | 48.42 |
| 2022-12-31 | $22k | 600 | 36.67 |
| 2022-09-30 | $115k | 2.3k | 50.00 |
| 2022-06-30 | $456k | 11k | 40.00 |
| 2022-03-31 | $14k | 400 | 35.00 |
| 2021-03-31 | $677 | 143 | 4.73 |
| 2020-12-31 | $688 | 113 | 6.10 |
| 2020-09-30 | $2.0k | 422 | 4.67 |
| 2020-06-30 | $1.6k | 322 | 5.07 |
| 2020-03-31 | $1.6k | 357 | 4.46 |
| 2019-12-31 | $2.1k | 438 | 4.80 |
| 2019-09-30 | $2.7k | 803 | 3.38 |
| 2019-06-30 | $297 | 66 | 4.50 |
| 2019-03-31 | $628 | 167 | 3.76 |
| 2018-12-31 | $181 | 53 | 3.42 |
| 2018-09-30 | $376 | 80 | 4.70 |
| 2018-06-30 | $182 | 54 | 3.37 |
| 2018-03-31 | $84k | 418 | 200.96 |
| 2017-12-31 | $13k | 77 | 168.83 |
| 2017-09-30 | $102k | 431 | 236.66 |
| 2017-06-30 | $67k | 200 | 335.00 |
| 2017-03-31 | $87k | 580 | 150.00 |
| 2016-12-31 | $257k | 1.2k | 208.27 |
| 2016-09-30 | $163k | 620 | 262.90 |
| 2016-06-30 | $23k | 400 | 57.50 |
| 2016-03-31 | $18k | 702 | 25.64 |
| 2015-12-31 | $104k | 399 | 260.65 |
| 2015-09-30 | $152k | 542 | 280.44 |
| 2015-06-30 | $47k | 265 | 177.36 |
| 2015-03-31 | $65k | 85 | 764.71 |
Top funds holding Ptc Therapeutics
View all funds holding Ptc Therapeutics